BANAGALORE, May 5 (Reuters) - Shares of InterMune Inc crashed 78 percent after U.S. health regulators declined to approve its lung drug, raising doubts about the drug's future. Sign up here. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback